S-1/A: Adagio Medical Holdings Files Amendment to S-1 Registration Statement, Updating Executive Compensation

Adagio Medical Holdings updates its S-1 registration statement to reflect executive compensation for the fiscal year ended December 31, 2024, with no additional securities being registered.

Summary

• Adagio Medical Holdings, Inc. filed a pre-effective amendment to its existing S-1 registration statement.
• The amendment updates the Executive Compensation section to reflect compensation paid in the fiscal year ended December 31, 2024.
• No additional securities are being registered under this amendment.
• The prospectus relates to the potential offer, sale, or disposition of up to 31,818,652 shares of common stock by selling stockholders.
• These shares include Registration Delay Shares, Convertible Note Shares, and Warrant Shares.
• Adagio Medical Holdings is an emerging growth company and has elected to comply with reduced public company reporting requirements.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol ADGM.
• On February 3, 2025, the last reported sales price of the common stock was $1.24 per share.
• The company will not receive any proceeds from the sale of shares of Common Stock by the selling stockholders, except with respect to amounts received by us upon the exercise of any warrants for cash.
• The company will receive up to an aggregate of approximately $14.4 million from the exercise of the Warrants, assuming exercise in full of all the Warrants for cash.
• The company expects to use the net proceeds from the exercise of the Warrants for general corporate purposes.

Sentiment

Score: 5

Explanation: The document is a regulatory filing, primarily factual, with some potential risks highlighted. The sentiment is neutral.

Positives

• The company is updating its registration statement to provide current information to investors.
• The company has the potential to receive up to $14.4 million from the exercise of warrants.
• The company has flexibility in how it uses the proceeds from warrant exercises.

Negatives

• The company will not receive any proceeds from the sale of shares of Common Stock by the selling stockholders.
• The market price of the company's Common Stock is lower than the exercise prices of the Warrants as of the date of this prospectus.
• The sale of all the securities being offered in this prospectus, or the perception that these sales could occur, could result in a significant decline in the public trading price of our securities.

Risks

• The sale of all the securities being offered in this prospectus, or the perception that these sales could occur, could result in a significant decline in the public trading price of our securities.
• The likelihood that warrant holders will exercise their Warrants for cash and therefore the amount of cash proceeds that we would receive, is dependent upon the trading price of our Common Stock.
• If the trading price for our Common Stock is less than the exercise price of the Warrants, meaning the Warrants are out of the money, we believe the holders of Warrants will be unlikely to exercise these Warrants.

Future Outlook

The company expects to use the net proceeds from the exercise of the Warrants for general corporate purposes.

Industry Context

The document does not provide specific details about the broader industry trends or competitors beyond the general statement of being an emerging growth company.

Stakeholder Impact

• The sale of all the securities being offered in this prospectus, or the perception that these sales could occur, could result in a significant decline in the public trading price of our securities.
• The future exercise of registration rights may adversely affect the market price of our Common Stock.
• The Perceptive PIPE Investor has control over key decision making as a result of its control of a majority of the voting power of our outstanding Common Stock.
• Our stock price may be volatile and may decline regardless of its operating performance.
• We may be unable to maintain the listing of our securities on Nasdaq in the future.
• Future sales of shares by existing stockholders could cause our stock price to decline.
• We may issue additional shares of common stock or other equity securities without your approval, which would dilute your ownership interests and may depress the market price of our common stock.

Next Steps

• The selling stockholders may offer, sell or distribute all or a portion of the securities hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices.
• The company will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or blue sky laws.

Key Dates

Keywords

registration statement, common stock, executive compensation, securities, warrants, convertible notes, Adagio Medical Holdings, selling stockholders, emerging growth company